Texas

Resilience System


You are here

Future COVID shots should target JN.1, KP.2 subvariants --US FDA staff

Primary tabs

 

The FDA reviewers said since the difference between JN.1 and newer subvariants such as KP.2 subvariants is not much, it is possible that vaccines developed against JN.1 may adequately protect against KP.2.
 
But, the reviewers added that further evolution of the virus could take it away from JN.1, so vaccine makers may need to consider updating their vaccine to the currently predominant variant....
Country / Region Tags: 
Problem, Solution, SitRep, or ?: 
Groups this Group Post belongs to: 
- Private group -
howdy folks
Page loaded in 0.423 seconds.